Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway

NCT04200911 ↗

Phase 0 Completed 10 enrolled The University of Texas Health Science Center at San Antonio National Center for Advancing Translational Sciences (NCATS) · collab

NaSingle-groupOpen-labelTreatment

Summary

Evaluation of central nervous system penetration of orally administered Rapamune (RAPA) in older adults with Mild Cognitive Impairment (MCI) or early Alzheimer's disease (AD) and investigate associated safety, tolerability, target engagement, cognition, and functional status as initial proof-of-concept study

Timeline

Start: 2020-06-01
Primary completion: 2022-01-13
Completion: 2022-01-13

Publications

Gonzales MM, Garbarino VR, Kautz TF, Song X, Lopez-Cruzan M, Linehan L, Van Skike CE, De Erausquin GA, Galvan V, Orr ME, Musi N, He Y, Bateman RJ, Wang CP, Seshadri S, Kraig E, Kellogg D Jr. Rapamycin treatment for Alzheimer's disease and related dementias: a pilot phase 1 clinical trial. Commun Med (Lond). 2025 May 20;5(1):189. doi: 10.1038/s43856-025-00904-9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sirolimus	Small molecule	1 mg	Oral

Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway

Summary

Timeline

Publications

Drugs

Indications